Literature DB >> 14601076

Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.

Samira Syed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14601076     DOI： 10.1002/cncr.11788

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

1.  Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer.

Authors:  Raj Kumar; Sowmyalakshmi Srinivasan; Pallab Pahari; Jürgen Rohr; Chendil Damodaran
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

Review 2.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger
Journal:  Cancer Lett       Date:  2009-08-29       Impact factor: 8.679

3.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

Review 4.  Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.

Authors:  Zachary S Dovey; Sujit S Nair; Dimple Chakravarty; Ashutosh K Tewari
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.